SCHEMBL4675734

SCHEMBL4675734

O=C(C=C(O)c1nc[nH]n1)c1cc(Cc2cccc(F)c2)co1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.40
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
BRS3 P32247 1/20 0.36
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
NR4A2 P43354 2/20 0.34
NR3C2 P08235 1/20 0.34
GSK3B P49841 1/20 0.34
BACE1 P56817 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GPR52 Q9Y2T5 1/20 0.33
SNCA P37840 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP12 P39900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679147 0.89 PTGER4 (0.35) HCAR2KDM5AKDM4CKDM5BLMNA
SCHEMBL4673435 0.89 LMNA (0.36) BRS3LMNAKMT2A
SCHEMBL4673040 0.88 HCAR2 (0.40) HCAR2KDM4CKDM5BBRS3LMNA
SCHEMBL4673646 0.87 NR4A2 (0.38) NR4A2NR3C2MEN1KMT2AGPR52
SCHEMBL4675382 0.86 KDM4C (0.41) KDM4CKDM5BBRS3LMNAPOLB
SCHEMBL4671423 0.84 HCAR2 (0.39) HCAR2KDM5AKDM4CKDM5BLMNA
SCHEMBL4671807 0.84 HCAR2 (0.40) HCAR2KDM5AKDM4CKDM5BBRS3
SCHEMBL4670907 0.84 BRS3 (0.35) KDM5AKDM5BBRS3NR3C2MEN1
SCHEMBL4675468 0.84 HCAR2 (0.40) HCAR2KDM5AKDM4CKDM5BBRS3
SCHEMBL4678994 0.83 NR4A1 (0.38) NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885KDM5A 1534/4885KDM4C 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.